Point-of-Care Molecular Diagnostics
Latin America · 2 shared keywords
Updated
Reviewed by Vidhi Upadhyay
Latin America Infectious Disease Molecular Diagnostics Market Industry Trends and Forecast to 2034: Segmented by (Disease, Technology, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$478.8 Mn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $700.3 Mn | — | — |
| 2025 (base) | $740.2 Mn | +$39.9 Mn | — |
| 2026 (forecast) | $782.4 Mn | +$42.2 Mn | +5.7% |
| 2027 (forecast) | $827.0 Mn | +$44.6 Mn | +11.7% |
| 2028 (forecast) | $874.1 Mn | +$47.1 Mn | +18.1% |
| 2029 (forecast) | $923.9 Mn | +$49.8 Mn | +24.8% |
| 2030 (forecast) | $976.6 Mn | +$52.7 Mn | +31.9% |
| 2031 (forecast) | $1.03 Bn | +$55.7 Mn | +39.5% |
| 2032 (forecast) | $1.09 Bn | +$58.8 Mn | +47.4% |
| 2033 (forecast) | $1.15 Bn | +$62.2 Mn | +55.8% |
| 2034 (forecast) | $1.22 Bn | +$65.7 Mn | +64.7% |
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
| Market size, 2025 | $740.2 Mn placeholder estimate |
|---|---|
| Forecast, 2034 | $1.22 Bn placeholder estimate |
| Growth (CAGR), 2025–2034 | 5.7% placeholder estimate |
| Years | 2024 historical · 2025 base year · 2026–2034 forecast |
| Segments | Disease, technology and end user (see all) |
| Key players | Roche Diagnostics, Abbott Laboratories, Hologic, Inc., Cepheid, bioMérieux SA (see all) |
| Formats | PDF, PPTX, XLSX |
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
Infectious disease molecular diagnostics detect the DNA or RNA of germs to diagnose infections accurately and quickly.
Key segments of the infectious Disease Molecular Diagnostics market include disease (Respiratory, HIV and Hepatitis and STIs) and technology (PCR, Isothermal and Sequencing).
Demand for earlier and faster diagnosis, growth of testing outside hospitals, new molecular technologies and the shift to preventive care are driving the infectious Disease Molecular Diagnostics market.
Home testing, connected devices that send results to doctors and multiplex tests that check many conditions at once give the infectious Disease Molecular Diagnostics market room to grow, especially in emerging markets.
Pricing pressure, uneven reimbursement for new tests, regulatory approval times and the need for skilled lab staff hold back the infectious Disease Molecular Diagnostics market.
The infectious Disease Molecular Diagnostics market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
In some of the countries we cover here, medical devices are regulated by ANVISA (Brazil)[1], ARCSA (Ecuador)[2], COFEPRIS (Mexico)[3], ANMAT (Argentina)[4], INVIMA (Colombia)[5] and ISP (Chile)[6]. How care is paid for in some of these countries: the SUS (Brazil)[7]; public care and IESS (Ecuador)[8]; IMSS, ISSSTE and IMSS-Bienestar (Mexico)[9]; public care, obras sociales and prepaid plans (Argentina)[10]; social health insurance (EPS) (Colombia)[11]; and FONASA and ISAPREs (Chile)[12].
[1] ANVISA. Checked 14 Nov 2026.
[2] ARCSA. Checked 14 Nov 2026.
[3] COFEPRIS. Checked 14 Nov 2026.
[4] ANMAT. Checked 19 Nov 2026.
[5] INVIMA. Checked 19 Nov 2026.
[6] Institute of Public Health of Chile (ISP). Checked 19 Nov 2026.
[7] CONITEC. Checked 14 Nov 2026.
[8] Ministry of Public Health of Ecuador. Checked 14 Nov 2026.
[9] Mexican Social Security Institute (IMSS). Checked 14 Nov 2026.
[10] Superintendence of Health Services (SSSalud). Checked 19 Nov 2026.
[11] Ministry of Health and Social Protection. Checked 19 Nov 2026.
[12] FONASA. Checked 19 Nov 2026.
Medical device rules, such as the US FDA 510(k) and PMA pathways and the EU Medical Device Regulation, govern how infectious Disease Molecular Diagnostics products are approved and monitored. Reimbursement codes and hospital purchasing policies decide how widely they are used in Latin America.
What doctors and scientists are doing in Infectious Disease Molecular Diagnostics right now, from free public sources.
Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
From our blog
Latin America · 2 shared keywords
Latin America · 1 shared keyword
Latin America · 1 shared keyword
Latin America · 1 shared keyword
Latin America
Latin America
Digital Health · Latin America
Healthcare Services · Latin America
Pharmaceuticals · Latin America
OTC & Nutraceuticals · Latin America
Pharmaceuticals · Latin America
Healthcare Services · Latin America